Arvind Sreedharan
Direttore operativo presso Neurogene, Inc.
Profilo
Arvind Sreedharan is currently the Director at Huntington Study Group.
He also holds the position of Senior Vice President-Business Operations at Neurogene, Inc. (New York) and Neurogene, Inc. Mr. Sreedharan previously worked as the Director-Movement Disorders at Lundbeck, Inc. and as the Vice President-Marketing at Auspex Pharmaceuticals, Inc. Additionally, he served as a Trustee at Huntington's Disease Society of America and as the Vice President-US Commercial Operations at Novartis Gene Therapies, Inc. Mr. Sreedharan completed his undergraduate degree at UNC School of Medicine.
Posizioni attive di Arvind Sreedharan
| Società | Posizione | Inizio |
|---|---|---|
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Direttore operativo | - |
| Huntington Study Group | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Arvind Sreedharan
| Società | Posizione | Fine |
|---|---|---|
| Huntington's Disease Society of America | Direttore/Membro del Consiglio | - |
| AUSPEX PHARMACEUTICALS INC | Vendite & Marketing | - |
Lundbeck, Inc.
 Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Corporate Officer/Principal | - |
| AVEXIS INC | Corporate Officer/Principal | - |
Formazione di Arvind Sreedharan
| UNC School of Medicine | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
Lundbeck, Inc.
Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Health Technology |
| Huntington's Disease Society of America | |
| Huntington Study Group |
- Borsa valori
- Insiders
- Arvind Sreedharan
